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Abstract
There has been increasing interest in instrumental variables regression for causal in-
ference. In genetics, transcriptome-wide association studies (TWAS), also known as
PrediXcan, have recently emerged as a widely applied tool to discover causal/target
genes by integrating an outcome GWAS dataset with another gene expression/ tran-
scriptome GWAS (called eQTL) dataset; they can not only boost statistical power
but also offer biological insights by identifying (putative) causal genes for a GWAS
trait, e.g. low-density lipoprotein cholesterol (LDL). Statistically TWAS apply (two-
sample) two-stage least squares (2SLS) with multiple correlated SNPs as instrumental
variables (IVs) to predict/impute gene expression, in contrast to typical (two-sample)
Mendelian randomization (MR) approaches using independent SNPs as IVs, which
are expected to be lower-powered. However, some of the SNPs used may not be valid
IVs as a result of their (horizontal) pleiotropic/direct effects on the trait not medi-
ated through the gene of interest, leading to false conclusions by TWAS (or MR). We
propose a general inferential method for possibly high-dimensional data to account
for confounding and invalid IVs while selecting valid IVs simultaneously via two-stage
constrained maximum likelihood; we develop a theory for the likelihood method sub-
ject to a truncated L1-constraint approximating the L0-constraint for asymptotically
valid and efficient statistical inference on causal effects. We demonstrate both theo-
retically and numerically the superior performance of the proposed method over the
standard 2SLS/TWAS and other methods. We apply the methods to identify causal
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Chapter 1
Introduction
Transcriptome-wide association studies (TWAS), as implemented in PrediXcan [12]
and TWAS [15], were recently proposed to boost statistical power and enhance in-
terpretation. It was motivated by one key hypothesis that many genetic variants
influence complex traits through transcriptional regulation. They have soon become
popular with applications to common diseases like type 2 diabetes, schizophrenia,
and cancer, convincingly showing the power of integrating genome-wide association
studies (GWAS) and expression quantitative trait locus (eQTL) data to gain biolog-
ical insights. Specifically, TWAS implicate (putative) causal genes of a GWAS trait,
overcoming a severe limitation of GWAS in a lack of biological insights from GWAS
discoveries of trait-associated genetic variants. Statistically TWAS apply the stan-
dard (two-sample) two-stage least squares (2SLS) in the framework of instrumental
variable (IV) regression for causal inference. IV regression is a general and powerful
tool for estimating and drawing inference about a causal effect from the exposure to
an outcome in the presence of unmeasured confounding. A valid IV must satisfy three
assumptions:
(A). Relevance: it is associated with the exposure;
(B). Exchangeability: it is not associated with unmeasured confounders;
1
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(C). Exclusion restriction: it is not associated with the outcome conditional on the
exposure.
Given valid IVs, 2SLS makes a correct inference about the causal effect; yet it may
break down and give erroneous results in the presence of invalid IVs. Assumption
(A) ensures the inclusion of relevant IVs, which is more straightforward and typically
possibly more conservatively handled by using a stringent significance cut-off. In
contrast, testing assumptions (B) or (C) is more challenging; between (B) and (C),
the former is even harder (due to the hidden confounding) while the existing literature
(especially concerning MR) is more focused on (C). As to be discussed, the proposed
method can deal with the violation of all three assumptions. Kang et al. [17] proposed
a lasso-type method called sisVIVE for estimating causal effect with some invalid IVs
but did not address the problem of inference. Lin et al. [18] proposed a two-stage
regularization method to select optimal instruments and jointly estimate the effects
of multiple exposures on the outcome, but they did not allow invalid IVs in stage 2
and did not consider the problem of inference either. Windmeijer et al. [36] proposed
a two-stage method to make inference about the causal effect in the low-dimensional
setting with a fixed number of instruments. Because of the median estimator used
in the first stage, their method requires the “Majority Condition", that is, more than
50% of the instruments are valid. When the “Majority Condition" fails but a weaker
“Plurality Condition" holds, Two-Stage Hard Threshold (TSHT) by Guo et al. [14]
can handle inference in the low-dimensional situation with the oracle property; for the
high-dimensional case, TSHT can consistently estimate the set of valid instruments
and then make correct inference but without the oracle property. Importantly, the
aforementioned works all deal with the one-sample case, in which the data used for the
two-stage modeling are collected from the same sample of individuals. In contrast,
the two-sample case has dominated recent genetic applications in TWAS and MR
as to be discussed later, in which the exposure and the outcome data are from two
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independent samples.
We propose a Two-Stage Constrained Maximum Likelihood (2ScML) method to
make inference on causal effects in the framework of instrumental variables regres-
sion as 2SLS. First, we aim to tackle the problem in a more general setting than
that of many other methods. In particular, we allow high-dimensional data in the
presence of invalid IVs with all three IV assumptions violated. Compared to some
existing methods with two different initial and final estimators, we propose a unified
constrained regression approach for simultaneous variable selection, accounting for
invalid IVs and drawing inference at the same time. Second, in contrast to TSHT,
in the high-dimensional setting, our method can consistently identify the set of in-
valid instruments in the second stage and thus has the oracle property. Third, we
extend our method to GWAS summary data, largely broadening its applications to
genetics where individual-level data from large-scale GWAS are often unavailable. In
particular, the two-sample design has dominated recent genetic studies with easy and
wide applications to two independent GWAS summary datasets on exposure and an
outcome respectively. For this purpose, we develop our method for the two-sample
case, in addition to the one-sample case. We also propose BIC for consistent model
selection; it is applicable with either GWAS individual-level data or summary data.
We are not aware of any other existing methods with all the above features of our
proposed method.
The proposed method is especially suitable for applications to TWAS to iden-
tify causal genes or other molecular/imaging/clinical endophenotypes by integrating
GWAS with other eQTL/xQTL data [12, 15, 44, 45, 38, 39, 30, 6, 16]. In these
applications, multiple correlated SNPs (so-called cis-SNPs) near a gene are used as
IVs to impute or predict the gene’s expression level (or another endophenotype) to
infer whether the gene’s expression (or another risk factor) has a causal effect on a
trait, say low-density lipoprotein cholesterol (LDL). However, due to strong modeling
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assumptions on valid IVs that may be violated frequently in practice, cautions have
to be taken about the conclusions from the standard TWAS. For example, it is known
that TWAS tends to identify multiple genes per locus, most of which are likely false
positives due to confounding caused by linkage disequilibrium (LD) among nearby
SNPs [19, 34, 37]. In particular, due to confounding through LD between an eQTL
(i.e. an SNP causal to a gene’s expression) and a true causal SNP to a GWAS trait,
a target gene identified by TWAS (or MR) may be only marginally associated with,
but not causal to, the GWAS trait, similar to that of a significant tagging SNP in
GWAS may not be causal. Furthermore, due to widespread (horizontal) pleiotropy
[33], some SNPs used in TWAS may not be valid IVs, again leading to violations
of a critical assumption in TWAS/2SLS [3, 5]. As alternatives to TWAS, another
class of popular IV analysis using (often independent) SNPs as IVs is (two-sample)
Mendelian randomization (MR) [8, 9, 10]. In these applications, due to often a small
sample size of an eQTL study (i.e. Stage 1 in 2SLS), it would be low powered to apply
a single SNP/IV-based method as in MR, as implemented in SMR and GSMR for the
same purpose [44, 45]; instead, it would be more powerful and thus more desirable
to apply a method with multiple SNPs used to predict the gene’s expression level (or
another exposure/trait in the first stage). Furthermore, an MR method, requiring
every single SNP to be a valid IV and thus to be associated with the exposure (i.e.
a gene’s expression level), in contrast to that the collection of the multiple SNPs to
be associated with the exposure in TWAS, will be more likely to encounter the bias
problem of weak IVs. For these two reasons, we will focus on TWAS, not MR or its
extensions (e.g. some popular ones reviewed in [29] or new ones described in [31, 42]),
though we will briefly compare with a new and perhaps the most popular MR ap-
proach called Egger regression, which is robust in the presence of invalid IV with IV
Assumption (C) violated [4]. However, if IV Assumption (B) is violated, MR-Egger
regression would break down, as to be shown in our simulation study; besides, we will
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show much higher statistical efficiency/power of our new method over MR-Egger re-
gression. Finally, we also point out that the proposed method, as a general extension
to 2SLS, can be also applied to other problems, e.g. inferring causal relationships




We denote an exposure as D ∈ R, an outcome of interest as Y ∈ R, p IVs (such as
SNPs) as Z ∈ Rp. In the following, for a subset G ⊆ S = {1, 2, · · · , p} and vector
V ∈ Rp, VG is the corresponding sub-vector of V . Suppose we have n i.i.d. samples
{(Yi, Di,Zi)|i = 1, · · · , n}. Corresponding to the true causal model in Figure 2.1, our



















) are the error terms independent of instruments
Zi; γ0 ∈ Rp are the true effects of the IVs on the exposure, and for some A ⊆ S,
γ0A 6= 0, γ0Ac = 0; β0 ∈ R is the parameter of interest, representing the causal effect of
D on Y ; α0 ∈ Rp are the direct effects of the IVs on Y , and for some B ⊆ S, α0B 6= 0,
α0Bc = 0, and |B| = p0. Note that, if B is not empty, it explicitly accounts for the
violation of IV assumptions (B) or/and (C), a main problem to be addressed here.
Subsequently, we assume that by default the above two-stage linear models in
6
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Figure 2.1: The true causal model for (2.1). Directed edges represent direct effects;
both γ0A and α0B are non-zero; depending on whether β0 6= 0 or not, D has or does














(2.1) hold for all our later theorems. We also note that after centering all variables
at the sample mean 0, we do not have the intercepts in the two models in (2.1).
One primary aim is to infer β0 or the causal effect of the exposure Di on the
outcome Yi. Note that in general Di and εi are not independent due to σ12 6= 0;
for this reason, even under the low-dimensional setting, the ordinary least squares
(OLS) gives a biased estimate of β0 (both in finite samples and asymptotically), and
2SLS in the general framework of instrument variable regression has been proposed
for (asymptotically) unbiased inference. The two models in (2.1) correspond to that
for the two stages, respectively.
In what is to follow, we use the following notations: Y = (Y1, · · · , Yn)T ∈ Rn×1,
D = (D1, · · · , Dn)T ∈ Rn×1, Z = (Z1, · · · ,Zn)T ∈ Rn×p, ε = (ε1, · · · , εn)T ∈ Rn×1,
ξ = (ξ1, · · · , ξn)T ∈ Rn×1. For any set G ⊆ S, we use ZG to denote the corresponding
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columns of matrix Z. We assume that ZA and ZB are of full rank in column. For
any matrix X, PX = X(XTX)−1XT is the projection matrix to the column space of
X, and MX = I−PX is the residual projection matrix. Xij is the element in the ith
row and jth column of X.
The Plurality Condition, as stated in Guo et al. [14], is both sufficient and nec-
essary for parameter identifiability in model (2.1). For completeness we show the
theorem; see [14] for a proof.
Theorem 1. (Guo et al. 2018) Assume that E(ZiZTi ) is invertible. Then model
(2.1) is identifiable if and only if the Plurality Condition holds:
|A ∩Bc| > max
c 6=0
|j ∈ A : αj/γj = c|.
Here A∩Bc is the set of valid IVs satisfying all three IV assumptions. The Plurality
Condition is always assumed in the following and we will not state it explicitly again.
2.2 One-Sample Case
2.2.1 Oracle Estimator
Suppose we have a sample of size n containing Z, D, and Y from model (2.1). In




||D − ZAγA||2, D̂ = ZAγ̂orA ,
(β̂or, α̂orB ) = argmin
β,αB
||Y − β · D̂ − ZBαB||2,
(2.2)
where || · || represents the L2-norm. By setting γ̂ori = 0 for i /∈ A, we can extend γ̂orA
to γ̂or; and by setting α̂ori = 0 for i /∈ B, we can extend α̂orB to α̂or. The following
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assumptions are made to ensure the uniqueness and desired properties of the oracle
estimator. Let X0 = (ZAγ0A,ZB).
Assumption 1. Assume ||MZBZAγ0A||2/n ≥ d0, where d0 is some positive constant.






































Assumption 1 says that ZAγ0A, the total effect of instruments ZA on exposure D, is
separated from the column space of instruments ZB, which have direct effects on
outcome Y . Moreover, the covariance matrices are required to converge. Theorem 2
describes some statistical properties of the oracle estimator.
Theorem 2. With Assumption 1 satisfied, the probability of the oracle estimator
β̂or defined in (2.2) being unique converges to 1 as n → ∞, and β̂or is a consistent
estimator of the true causal effect β0 with β̂or p−→ β0 as n → ∞. Furthermore, we
have
√
n(β̂or − β0) d−→ N(0, v), with variance v = (σ21 + 2σ12β0 + (β0)2σ22) · (Σ−1)11 −
(2σ12β
0 + (β0)2σ22) · (Σ−1ΨΣ−1)11. Under the null hypothesis H0: β0 = 0, we have
v = σ21 · (Σ−1)11. Here σ21, σ22, σ12 are the variances and covariance of the error terms
as defined in (2.1).
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A consistent estimator of the asymptotic variance v is






where v̂or1 and v̂or2 are consistent estimates of (σ21 + 2σ12β0 + (β0)2σ22) and σ21, and Σ̂or
and Ψ̂or are consistent estimates of Σ and Ψ, respectively. Details are given in the
Appendix.
2.2.2 New Method: Two-stage Constrained Maximum Likeli-
hood
The proposed method consists of two stages as an extension to 2SLS. In the first
stage, we solve a constrained maximum likelihood problem to select relevant IVs to
satisfy Assumption (A), as the approach of [28] for a general regression model:
γ̂ = argmin
γ




min(|γj|, τ1) ≤ K1, (2.3)
where 1
τ1
min(|γj|, τ1) [27] is the truncated L1-function for γj, which is a continuous
surrogate of the L0 loss I(γj 6= 0) with I(·) the indicator function. The tuning
parameter K1 can be interpreted as the number of non-zero components of γ0, and
the constrained problem (2.3) performs a best-subset-like (but computationally much
more efficient) search to select K1 relevant IVs. In practice, we chooseτ1 to be a small
value like 1× 10−5 and use cross-validation or BIC to estimate the optimal K1 from
a set of candidate integers.
Given γ̂, we obtain the predicted exposure as D̂i = Ziγ̂; denote D̂ =
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(D̂1, D̂2, · · · , D̂n)T . Then in the second stage we solve constrained minimization:
(β̂, α̂) = argmin
β,α




min(|αj|, τ2) ≤ K2. (2.4)
Again, we choose τ2 to be a small value like 1 × 10−5 and use cross-validation or
BIC to estimate the optimal K2, or the number of invalid IVs. Here we model the
direct effects of the IVs explicitly, and use the non-convex constraint to select and
thus account for invalid IVs that violate the IV Assumptions (B) and (C).
It is noted that, under the normality assumption, in each stage, the objective
function of the proposed method is the squared error loss function as used in 2SLS,
though a truncated L1 constraint (TLC) is imposed to select relevant IVs and in-
valid IVs respectively in the two stages. We refer to our method as the constrained
maximum likelihood in anticipation of its extensions to other parametric models.
Define A = {A1
∣∣A1 ⊆ S, |A1| ≤ |A|, A1 6= A}, B = {B1∣∣B1 ⊆ S, |B1| ≤
p0, B1 6= B}, and G = {B1
∣∣B1 ⊆ S, |B1| ≤ p0, B1 6= B,A * B1}, and denote




Now we state the following assumptions.
Assumption 2. For some positive constants c1 and d1-d3,

































Assumption 3. Assume that
0 < τ1 ≤ σ2
√
6
(n+ 2) · p · cmax(ZTZ)
,
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and
0 < τ2 ≤ σM
√
6
(n+ 2) · p · cmax(ZTZ)
,
where cmax(·) denotes the largest eigenvalue of a matrix.
Assumption 4. For some positive constant d4,
Cmin 3 ≥ d4
(p0 + 2) log p
n1/3
σ22,





Assumption 2 says that ZAγ0A, the imposed effect of ZA on exposure D, is sep-
arated from the column space spanned by ZA1 for any A1 that is not identical to A
and contains no more than |A| IVs; and ZBα0B, the imposed direct effect of ZB on
outcome Y , is separated from the column space spanned by ZAγ0A and ZB1 for any
B1 that is not identical to B and contains no more than |B| = p0 IVs. Assumption
3 says that τ1 and τ2 are sufficiently small to have an adequate TLC approximation
to the L0-constraint. When A * B1, Assumption 4 ensures that ZAγ0A is separated
from the column space of ZB1 . Under Assumptions 1 to 4, Theorem 3 shows (β̂, α̂)
from (2.4) has the oracle property.
Theorem 3. Under Assumptions 1 to 4, if K1 = |A| and K2 = p0, then
P
(
(β̂, α̂) = (β̂or, α̂or)
)
→ 1, either as n→∞ with a fixed p, or as n, p→∞.





for some constant C as n→∞, the constrained maximum likelihood
estimator (β̂, α̂) asymptotically has the same performance as the oracle estimator
(β̂or, α̂or). Together with the asymptotic variance of β̂or from Theorem 2, we could
perform the Wald test with the constrained estimator (β̂, α̂).
Besides the Wald test, we can also perform the likelihood ratio test as in [43]. In
the second stage, we fit another constrained linear model of Y on Z only under the
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null hypothesis of β0 = 0, with the same K2 as in (2.4),
α̂(0) = argmin
α




min(|αj|, τ2) ≤ K2. (2.5)
Then, given (β̂, α̂) in (2.4), similar to [43], after profiling out the variance parameter
of the error term, we define the constrained maximum likelihood ratio (CMLR) as
Λn = n(log ||Y −Zα̂(0)||2 − log ||Y − β̂ · D̂ − Zα̂||2). (2.6)
Corollary 1. Assume that Assumptions 1 to 4 are met. If K1 = |A| and K2 = p0,
then under the null hypothesis of β0 = 0, Λn converges in distribution to χ21, a chi-
squared distribution with degrees of freedom 1, either as n→∞ with a fixed p, or as
both n, p→∞.
Based on Corollary 1, we can perform the likelihood ratio test. This test gives
almost the same results as those from the Wald test in our simulations and real data
analyses. So we will focus on the latter.
2.2.3 Tuning parameter selection with BIC
Given individual level data, we could choose K1 and K2 with cross-validation, but
we cannot do so with summary level data. Instead, we propose using Bayesian infor-
mation Criterion (BIC) [26] to select K1 and K2 in the two stages. For our target
applications in GWAS, the sample size n is at least a few thousands, much larger than
p, the number of IVs (SNPs) used, so here we consider BIC with low-dimensional data,
i.e. with a fixed p. For an extension to high-dimensional data, a modified BIC such as
in [7, 41] could be used but will not be pursued here. Denote the estimate from (2.3)
with constraint parameter K1 to be γ̂K1 , that from (2.4) with constraint parameter
2.3. Two-Sample Case 14





n · log(σ22) +




As σ22 is unknown, we plug in its maximum likelihood estimate σ̂22 = ||D − Zγ̂K1||2/n
and have the BIC for the first stage
BIC1(K1) = n · log
||D − Zγ̂K1 ||2
n
+ log(n) · ||γ̂K1||0. (2.7)
Similarly, BIC for the second stage is
BIC2(K2) = n · log
||Y − β̂K2 · D̂ − Zα̂K2||2
n
+ log(n) · ||α̂K2||0. (2.8)
We choose K̂1 = argminK1∈K1 BIC1(K1) and K̂2 = argminK2∈K2 BIC2(K2), where K1
and K2 are sets of candidate K1’s and K2’s, respectively. Theorem 4 shows that BIC
is consistent for tuning parameter selection in both stages with a fixed p.
Theorem 4. Assume that Assumptions 1 to 4 are met. Then, when p is fixed, if
|A| ∈ K1 and p0 ∈ K2, we have P
(
K̂1 = |A|, K̂2 = p0
)
→ 1 as n→∞.
2.3 Two-Sample Case
2.3.1 Oracle Estimator
Now we consider the case with the exposure and outcome data coming from two
independent samples, which has largely facilitated the wide application of TWAS
and MR with the availability of large-scale GWAS summary data on various traits.
Suppose we only observe Y and Z in a sample of size n from model (2.1) and obtain
an estimate γ̂A from another independent sample of size n2. Now the oracle estimator
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is defined as
D̂ = ZAγ̂A,
(β̂or, α̂orB ) = argmin
β,αB
||Y − β · D̂ − ZBαB||2.
(2.9)
Assumption 5. Assume that as n2 →∞, we have n/n2 → w for some positive and
finite constant w, and γ̂A ∼ N(γ0A, σ22Θ) with n2Θ→ Θ0 as n2 →∞.
Assumption 5 states that the sample sizes of the two independent samples, n and
n2, should be in the same order, and γ̂A should be a consistent and asymptotically
normal estimator of the true γ0A. For example, we can apply the maximum likelihood
or least-squares estimator to an independent sample of size n2,
D2 = Z2γ
0 + ξ2. (2.10)

















Θ0 (UAγ0A UAB). Theorem 5 gives some statistical
properties of the two-sample oracle estimator.
Theorem 5. With Assumptions 1 and 5 satisfied, the probability of the oracle esti-
mator β̂or defined in (2.9) being unique converges to 1 as n, n2 → ∞, and β̂or is a
consistent estimator of true causal effect β0 with β̂or p−→ β0 as n, n2 → ∞. Further-
more, we have
√




−1)11. Under the null hypothesis H0: β0 = 0, we have
v = σ21 · (Σ−1)11.
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A consistent estimator of the asymptotic variance v is










where v̂or1 and σ̂22 are consistent estimates of (σ21 + 2σ12β0 + (β0)2σ22) and σ22, Σ̂or and
Ψ̂or2 are consistent estimates of Σ and Ψ2, and n and n2 are the sample sizes for the
two stages, respectively. Details are given in the Appendix.
2.3.2 New Method: Two-stage Constrained Maximum Likeli-
hood
As for the two-sample oracle estimator, with γ̂A calculated from one sample, we obtain
the predicted exposure as D̂ = ZAγ̂A for the other independent sample. Then we
solve in the second stage a constrained minimization as in (2.4) to obtain the 2ScML
estimator. Under Assumption 1, ZTAZA/n→ UA, so we can get a finite upper-bound
of the eigenvalues of ZTAZA/n as u1. Similarly, from Assumption 5, we obtain a finite
upper-bound of the eigenvalues of n2Θ as u2, and a finite upper-bound of n/n2 as u3.
For two-sample 2ScML, we substitute Assumption 2 by Assumption 6.
Assumption 6. Denote σ2M = σ21 + 2σ12β0 + σ22(β0)2 + u1u2u3(β0)2σ22, σ2m = σ21 +
2σ12β
0 + σ22(β
0)2, r = 2σM
σm
. For some positive constants d2 and d3,






















Theorem 6 shows the 2ScML estimator has the oracle property.
Theorem 6. Under Assumptions 1, 3, 4, 5 and 6, if K2 = p0, then
P
(
(β̂, α̂) = (β̂or, α̂or)
)
→ 1, either as n→∞ with a fixed p, or as both n, p→∞.
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Similar to the one-sample case, we can also perform the likelihood ratio test for
the two-sample case, with α̂(0) and CMLR defined in (2.5) and (2.6) respectively.
Corollary 2. Assume that Assumptions 1, 3, 4, 5 and 6 are met. If K2 = p0, then
under the null hypothesis of β0 = 0, Λn converges in distribution to χ21, a chi-squared
distribution with degrees of freedom 1, either as n → ∞ with a fixed p, or as both
n, p→∞.
2.3.3 Tuning parameter selection with BIC
For the two-sample case, as we assume a consistent estimator γ̂A in the first stage,
we consider using BIC to select K2 in the second stage. Denote the estimate from
(2.4) with K2 as (β̂K2 , α̂K2), then BIC has a form similar to (2.8). For a candidate set
K2 of K2’s, we choose K̂2 = argminK2∈K2 BIC2(K2). Theorem 7 shows the selection
consistency of BIC in the second stage with a fixed p.
Theorem 7. Assume that Assumptions 1, 3, 4, 5 and 6 are met. Then when p is




→ 1 as n→∞.
2.4 Computation
To solve the nonconvex constrained minimization (2.3), we use a difference convex
(DC) method to approximate the nonconvex constraint with a sequence of convex
constraints iteratively. First, we decompose the constraint function into a difference










|γj| −max(|γj| − τ1, 0). (2.12)
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Given an estimate γ(m)j at the mth iteration, the subgradient of max(|γj| − τ1, 0) at
|γ(m)j | is I(|γ
(m)
j | > τ1). Then,
max(|γj| − τ1, 0) ≥ max(|γ(m)j | − τ1, 0) + (|γj| − |γ
(m)
j |) · I(|γ
(m)
j | > τ1). (2.13)










|γj| −max(|γ(m)j | − τ1, 0)− (|γj| − |γ
(m)
j |) · I(|γ
(m)










On this ground, at the mth iteration, we relax the nonconvex minimization (2.3) to
the following convex constrained minimization
γ̂ = argmin
γ











Solving (2.15) is equivalent to solving a constrained lasso problem, which can be solved
by an algorithm in [21]. Similarly, we iteratively relax nonconvex minimization (2.4)
to
(β̂, α̂) = argmin
β,α












Again, the algorithm of [21] is applied to solve the constrained lasso problem (2.16).
This process continues until a termination criterion is met.
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2.5 Extension to GWAS Summary Data
We extend the proposed 2ScML to a situation with only GWAS summary statistics
and a reference panel. For a certain trait or outcome Y , a GWAS is performed to
assess possible associations between the SNPs and Y . By performing marginal linear
regression of Y on each SNP Z separately, we estimate the marginal effect size of Z
on Y as β̂Y Z along with its standard error se(β̂Y Z). Due to the logistic and privacy
issues, individual-level genotypes (i.e. Z’s) and phenotypes (i.e. Y ) are typically
not publicly available but only summary data in the form of β̂Y Z ’s and se(β̂Y Z)’s
are available for all SNPs/Z’s. From a reference panel, consisting of individual-level
genotype data of a group of individuals, such as from the 1000 Genomes Project [1],
we estimate the correlation structure among the SNPs. This generalization allows
our method to apply to some published large-scale GWAS summary data with a wide
range of traits to boost the power of statistical analysis.
For the constrained lasso problem in (2.15), it can be written as:
||D − Zγ||2 = DTD − 2DTZγ + γTZTZγ.
Recall that with individual level data, D ∈ Rn is a vector of the exposure values
for n individuals and Z ∈ Rn×p is the matrix of p IVs for n individuals. Without
loss of generality, we assume D and column vectors of Z are all standardized to
have sample mean 0 and sample variance 1, so DTD = n and DTZ/n ∈ Rp is a
vector of correlations between exposure and p IVs, ZTZ/n ∈ Rp×p is the correlation
matrix of p IVs. From the summary statistics of the exposure, we extract the vector
of correlations between exposure D and p IVs, denoted by rDZ ∈ Rp. From the
reference panel consisting of n0 individuals, we extract the values of p IVs denoted by
Z0 ∈ Rn0×p and estimate their correlation matrix as Σ0 ∈ Rp×p. Now in (2.15), we
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replace DTZ/n and ZTZ/n with their estimates rDZ and Σ0 respectively. Then
γ̂ = argmin
γ












When Σ0 is positive definite, which could be achieved by pruning out highly correlated
SNPs in the reference panel,
(
1− 2rTDZγ + γTΣ0γ
)
is bounded below and thus has





Then Σ1/20 is also positive definite with inverse Σ
−1/2


















which is a constrained lasso problem. Given γ̂, we obtain D̂ as a function of the
SNPs. Similarly, we obtain the correlations between Y and the SNPs, and between
Y and D̂ from the summary statistics for outcome Y , and solve (2.16) as before in
the second stage.
In the first stage, given K1, we obtain an estimate γ̂K1 . Paralleling with (2.7), the
BIC is
BIC1(γ̂K1) = n · log
(
1− 2rTDZγ̂K1 + γ̂TK1Σ0γ̂K1
)
+ log(n) · ||γ̂K1||0. (2.19)
Similarly, we select K2 using the BIC as (2.8) in the second stage.
When we draw inference about the causal effect of one trait on another, typically
GWAS summary data for both the exposure and outcome are available. In TWAS
applications, for each gene, the exposure D is its expression level, the IVs are some
eSNPs for this gene, and Y is some trait such as LDL. Often a GWAS summary
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dataset for gene expression (i.e. so-called eQTL data) is not available, so we cannot
perform the first stage analysis with 2SLS or 2ScML. Instead, some pre-calculated
γ̂’s, e.g. estimated from some publicly unavailable eQTL data by penalized regression
like Lasso or Elastic Net, are publicly available as from the TWAS Fusion website [15].
Our proposed 2ScML method here was motivated and is thus applicable with these
pre-calculated γ̂’s, from which we obtain D̂ in the second stage of 2ScML (or 2SLS)
with some GWAS summary data for Y as to be shown in our TWAS applications.
Chapter 3
Simulations
3.1 Simulation 1: One-Sample Case with IV As-
sumptions (A) and (C) Violated
We compare 2ScML with TSHT, naive-2SLS/TWAS, and oracle-2SLS through sim-
ulations, and the simulation setups closely follow those of TSHT [14]. Since TSHT,
as a state-of-the-art method, applied only to the one-sample case, we consider the IV
Assumptions (A) and (C) being violated in such a case. First we compare the Type-I
error rates of these methods. In Setup 1, we set the number of IVs p = 100, and
the sample size n varying at 100, 200, 300, 1000 and 2500. Instruments Z’s followed
a multivariate normal distribution with mean 0 and an AR(0.5) covariance matrix.
The error terms (ε, ξ) were generated from a bivariate normal distribution with mean
0, variances 1.5 and covariance 0.75. For 2 ≤ i ≤ 8, γ0i = 0.5; otherwise γ0i = 0; i.e.
the 2nd to 8th IVs were relevant with an equal effect size 0.5. For i = 7, 8, α0i = 0.5;
otherwise α0i = 0; i.e. the 7th and 8th instruments were invalid IVs with some direct
effects on the outcome. When β0 = 0, there was no causal effect from the exposure
to outcome, i.e. the null case. Setup 2 was similar to Setup 1 except: for i = 1, 7, 8, 9,
α0i = 0.5; otherwise α0i = 0; i.e. the relevant 7th and 8th instruments were invalid, and
the irrelevant 1st and 9th instruments were also invalid. Since the results for Setup 2
22
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Figure 3.1: Empirical Type-I error rates (left panel) and power (right panel) for





























5 Setup 1: Type−I Error







































were similar to those of Setup 1, we relegate the details to the Appendix.
In each simulation we generated n samples from the model in (2.1), then we applied
the four methods to the simulated data to test H0 : β0 = 0 versus H1 : β0 6= 0. For
2ScML, in the first stage, we used BIC to choose the best K1 ∈ {5, 6, 7, 8, 9, 10}; in
the second stage, we used BIC to choose the best K2 ∈ {0, 1, 2, 3, 4, 5}; and we set
τ1 = τ2 = 1× 10−5. For the naive-2SLS, in the first stage we used the 2nd to 8th IVs
to get D̂, then in the second stage we fitted a linear regression model of Y on D̂. The
oracle-2SLS had the same model as that of the naive-2SLS in the first stage, but in
the second stage we fitted a linear regression model of Y on D̂ and the 7th and 8th
IVs for Setup 1, or D̂ and the 1st, 7th, 8th and 9th IVs for Setup 2; in other words, we
included the 2 and 4 invalid IVs with direct effects in the stage 2 models for Setup 1
and Setup 2 respectively.
For each setup, we repeated the simulation 1000 times and set the nominal signif-
icance level at 0.05 for each n; Figure 3.1 summarizes the simulation result. We can
see that the oracle-2SLS could always have a Type-I error rate around the nominal
level 0.05, while naive-2SLS had a Type-I error rate dramatically inflated around 1.
When the sample size was small, TSHT and 2ScML both had large Type-I error rates;
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but as the sample size increased from 100 to 300, the Type-I error rate of 2ScML de-
creased fast, while that of TSHT remained large. When the sample size was large
enough, both TSHT and 2ScML could control the Type-I error rate at 0.05. It is
noted that, due to α07 = α08 = γ07 = γ08 = 0.5 for the two invalid IVs, it required larger
sample sizes for the two consistent estimation methods to distinguish the direct and
indirect effects of the IVs and thus maintain a correct Type-I error rate.
As to be seen from the left panel of Figure 3.1, when the sample size was 2500,
2ScML, TSHT, and oracle-2SLS could control their Type-I error rates. So we compare
their power at the sample size 2500: we changed β0 from −0.5 to 0.1 with a step size
of 0.02 and applied all four methods with 1000 independent replicates to calculate
their empirical power. Figure 3.1 (right panel) shows the results. Again, when β0 = 0,
i.e. with no causal effect, 2ScML, TSHT, and oracle-2SLS could control Type-I error
at 0.05, while naive-2SLS had its Type-I error inflated to 1. When |β0| was large,
2ScML, TSHT, and oracle-2SLS all had power 1. When |β0| was small, the power
of 2ScML and oracle-2SLS was very close and typically higher, and sometimes much
higher, than that of TSHT. For example, for β0 = −0.04, the empirical power of the
oracle and 2ScML was close at 0.746 and 0.738 respectively, much higher than that
of TSHT at 0.572. This supports the theory that 2ScML has the oracle property
while TSHT does not. We can see that for the range −0.3 < β0 < −0.22, naive-2SLS
had power smaller than 1, while the other three methods had power 1. This was not
surprising: the direct effects γ0 and α0 were positive, and the total effect of the IVs
on Y was β0 · γ0 +α0, so negative β0’s would diminish the total effect toward 0 and
thus decrease the power of naive-2SLS.
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3.2 Simulation 2: Two-Sample Case with IV As-
sumption (B) Violated
We compare 2ScML with perhaps the most popular method to deal with invalid IVs in
MR, MR-Egger regression [4], with simulated data. As required by MR, we consider
the two-sample case. Here we used p IVs Z1 to Zp, all of which were relevant to
exposure D (i.e. IV Assumption A was satisfied), but some of Z’s had direct effects
on outcome Y , and some of Z’s might have direct effects on unobserved confounder




0 + Ui + εD,i,
Yi = β
0 ·Di +Ziα0 + Ui + εY,i.
(3.1)
Here εU , εD, εY were independent random errors. φ0 were direct effects from Z’s to
U , γ0 were direct effects from Z’s to D, α0 were direct effects from Z’s to Y ; β0 was
the causal effect from D to Y , the parameter of interest. MR-Egger regression uses
summary statistics of Z’s on D, and Z’s on Y , from two independent datasets. It
requires Z’s are independent IVs, and all Z’s are relevant for D, i.e. γ0 are all non-
zero. α0 could be non-zero, i.e. IV assumption (C) could be violated, but α0 should
be independent of γ0; this is the so-called InSIDE assumption required by MR-Egger
regression. Accordingly, it does not allow non-zero φ0, i.e. the IV assumption (B)
should be satisfied. In contrast, as to be confirmed, our new method 2ScML allows
IV Assumption (B) to be violated, i.e. non-zero φ0.
We generated simulated data similar to the Case 3 with directional pleiotropy and
violated InSIDE assumption in [29]. We set the sample size n = 20000, generated p =
30 independent SNPs as Z’s with minor allele frequency (MAF) 0.3. We generated
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εU , εD, εY from a standard normal distribution with mean 0 and standard deviation
1. γ0’s were generated from truncated normal distribution with mean 0 and standard
deviation 0.2, and truncate at 0.1, i.e. all γ0’s having absolute values larger than
0.1; this was used to satisfy IV assumption (A). We had 30% invalid IVs, and we
chose them as the first 9 Z’s, and generated α01, · · · , α09 from a normal distribution
with mean 0.5 and standard deviation 0.075. φ01, · · · , φ09 were drawn from normal
distribution with mean 0 and standard deviation σφ. When σφ = 0, φ01, · · · , φ09
were all 0’s, implying IV Assumption (B) was satisfied; when σφ 6= 0, φ01, · · · , φ09
were non-zero, leading to IV Assumption (B) violated. We tried σφ = 0 or 0.1,
and β0 ∈ {−0.1,−0.05,−0.02,−0.01, 0, 0.01, 0.02, 0.05, 0.1}. In each simulation, we
generated two independent samples.
For MR-Egger regression, we calculated the summary statistics for D in the first
sample and for Y in the second sample, and used function mr_egger_regression()
from R package TwoSampleMR. For 2ScML, we used the first sample to calculate
γ̂ with linear regression and all 30 Z’s, then used γ̂ to get D̂ in the second sample,
and performed the second stage with τ2 = 1 × 10−5 and chose the best K2 from
7, 8, 9, 10, 11 with BIC, as the true number of invalid Z’s was 9. We also applied the
Oracle estimator, which had the same first stage as 2ScML, and in the second stage,
we included D̂ and the first 9 Z’s. For each setup, we did simulation 1000 times,
and calculated empirical Type-I error rates (for β0 = 0) and power (for β0 6= 0).
Figure 3.2 shows the simulation results.
From Figure 3.2 we can see that, in the upper panel when σφ = 0, i.e. when IV
Assumption (B) and thus the InSIDE assumption was satisfied, all three methods
could control the Type-I error rates well at the nominal level of 0.05 for β0 = 0;
for β0 6= 0, 2ScML and Oracle had similar power, much higher than MR-Egger. In
the lower panel when σφ = 0.1, i.e. when IV Assumption (B) and thus the InSIDE
assumption was violated, MR-Egger could not control its Type-I error rate, while
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Figure 3.2: Simulation 2: empirical Type I error rates (for β0 = 0) and power (for
β0 6= 0) when IV Assumption (B) was not (upper panel ) or was (lower) violated.
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Table 3.1: The means ( ¯̂β and S̄E(β̂)) of the estimates β̂ and their standard errors,
and the standard deviations (sd) of β̂ for MR-Egger, 2ScML and the oracle methods





β sd(β̂) S̄E(β̂) ¯̂β sd(β̂) S̄E(β̂) ¯̂β sd(β̂) S̄E(β̂)
-0.10 -0.0959 0.5370 0.5220 -0.1001 0.0132 0.0131 -0.1001 0.0131 0.0131
-0.05 -0.0466 0.5366 0.5219 -0.0503 0.0134 0.0134 -0.0503 0.0133 0.0134
-0.02 -0.0170 0.5364 0.5218 -0.0204 0.0136 0.0136 -0.0204 0.0135 0.0136
-0.01 -0.0071 0.5363 0.5217 -0.0104 0.0136 0.0136 -0.0104 0.0136 0.0136
0 0.0027 0.5362 0.5217 -4e-04 0.0137 0.0137 -4e-04 0.0136 0.0137
0.01 0.0126 0.5361 0.5217 0.0096 0.0138 0.0138 0.0095 0.0137 0.0138
0.02 0.0224 0.5360 0.5216 0.0196 0.0138 0.0138 0.0195 0.0137 0.0138
0.05 0.0519 0.5357 0.5215 0.0494 0.0141 0.0141 0.0494 0.0140 0.0141
0.10 0.1011 0.5353 0.5213 0.0993 0.0145 0.0145 0.0993 0.0144 0.0145
2ScML and Oracle could. Again 2ScML and Oracle had similar and much higher
power than MR-Egger.
Table 3.1 and Table 3.2 show the results in terms of estimating the causal effect size
β0. For σφ = 0, i.e. when the InSIDE assumption was satisfied, MR-Egger was nearly
unbiased, though the standard error (SE) of its estimate was much larger than those
from the other two methods, which were quite close to each other, explaining their
power properties as shown in Figure 3.2. When σφ = 0, i.e. the InSIDE assumption
was violated, the bias of MR-Egger was large. In contrast, 2ScML and Oracle always
gave negligibly small biases. For all three methods, when σφ = 0, the mean of the SE
estimates of β̂ was close to the corresponding standard deviation of β̂, sd(β̂), though
MR-Egger had much larger standard errors than those of 2ScML and Oracle, which
were quite close to each other, explaining their empirical Type I error rate and power
properties as shown in Figure 3.2. When σφ = 0.1, the means of SE(β̂) remained
close to sd(β̂) for 2ScML and Oracle, but were quite different for MR-Egger.
3.3. Other Simulations 29
Table 3.2: The means ( ¯̂β and S̄E(β̂)) of the estimates β̂ and their standard errors,
and the standard deviations (sd) of β̂ for MR-Egger, 2ScML and the oracle methods





β sd(β̂) S̄E(β̂) ¯̂β sd(β̂) S̄E(β̂) ¯̂β sd(β̂) S̄E(β̂)
-0.10 0.0662 0.5745 0.4629 -0.0990 0.0132 0.0130 -0.0990 0.0130 0.0130
-0.05 0.1163 0.5741 0.4628 -0.0491 0.0134 0.0133 -0.0491 0.0132 0.0133
-0.02 0.1463 0.5738 0.4627 -0.0192 0.0135 0.0134 -0.0192 0.0133 0.0134
-0.01 0.1562 0.5737 0.4627 -0.0093 0.0135 0.0135 -0.0093 0.0134 0.0135
0 0.1662 0.5736 0.4627 7e-04 0.0136 0.0136 7e-04 0.0134 0.0136
0.01 0.1762 0.5735 0.4626 0.0107 0.0137 0.0136 0.0107 0.0135 0.0136
0.02 0.1862 0.5734 0.4626 0.0207 0.0137 0.0137 0.0206 0.0136 0.0137
0.05 0.2161 0.5731 0.4625 0.0506 0.0139 0.0139 0.0505 0.0138 0.0139
0.10 0.2658 0.5726 0.4624 0.1004 0.0144 0.0144 0.1004 0.0142 0.0144
3.3 Other Simulations
In Appendix, we show the results from Simulation 3, demonstrating the good perfor-
mance of the proposed method with a realistic set-up using real genotypic data for a
gene and mimicking real TWAS data.
Chapter 4
Real Data Example
We applied 2ScML and the standard 2SLS/TWAS to identify (putative) causal genes
for LDL with GWAS summary statistics. Note that TSHT does not apply to GWAS
summary data, and thus cannot be compared here. For each gene, we used the TWAS
Fusion pre-calculated coefficients γ̂’s for our first stage analysis [15]; the coefficients
were estimated with elastic net regression based on microarray expression data of
blood from the Young Finns Study (YFS) with sample size 1264 [20, 23]. From the
1000 Genomes Project [1], we took 489 unrelated individuals of European ancestry
as our reference panel. The GWAS summary data of LDL were drawn from [32] with
sample sizes up to 95454; we removed the SNPs with sample sizes less than 80000.
We used software ImpG [22] to impute with the reference panel for the LDL GWAS
summary statistics. As stated in [22], we used the imputation accuracy measure r2
to quantify the imputation quality for each SNP and removed imputed SNPs with
r2 < 0.3.
There were 4700 genes with pre-calculated γ̂ in the TWAS Fusion database. For
each gene, we first identified the set of its eSNPs with non-zero coefficients γ̂. We
removed 120 genes with less than half of their eSNPs (with non-zero coefficients)
present in both the reference panel and GWAS summary data. We also pruned these
eSNPs to make their pairwise absolute correlations no larger than 0.9, and used the
30
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remaining p eSNPs to predict each gene’s expression as D̂ in the first stage analysis.
In the second stage we included D̂ and its eSNPs, and used BIC to select the best
K2 from {1, 2, · · · , d(p− 1)/2e}.
For each of the 4580 genes, we obtained its p-values from the standard TWAS
and our method, denoted as pTWAS and p2ScML respectively. After the Bonferroni
correction, we obtained 32 significant genes with at least one of their pTWAS and
p2ScML less than 0.05/4580; the standard TWAS and our new method identified 21
and 23 significant genes respectively, including 12 common ones. We did a literature
search on each of the 32 significant genes. We excluded the study generating the
LDL GWAS data we used [32]. Based on the literature support from other studies,
we assigned a score to each gene: if there were other studies (1) supporting this gene
being associated with LDL, we assigned the highest score of 5; (2) supporting this
gene associated with a trait related to LDL, we assigned a score of 4; (3) identifying
one or more SNPs mapped to or nearby this gene, which were significantly associated
with LDL, we assign a score of 3; (4) identifying some SNPs mapped to or nearby this
gene, which were significantly associated with other traits related to LDL, we assigned
it a score of 2; (5) identifying some SNPs mapped to or nearby this gene that were
significantly associated with any traits, we assigned a score of 1; (6) otherwise, we
assigned the lowest score of 0. See Appendix for a list of all the 32 genes with their
supporting references.
We compare the two sets of the p-values of the 32 genes obtained by the two
methods in Figure 4.1. For better visualization, we show the p-values in the − log10
scale. The left panel gives a scatter plot for all the 32 genes, while the right panel
zooms in; the vertical and horizontal green dashed lines represent the Bonferroni
adjusted significance cutoff 0.05/4580. The larger a score assigned to a gene (i.e.
with stronger literature support), the larger the size and the darker the color of its
corresponding point in the plot. Table 4.1 shows the 8 genes with a score of 4 or 5. It is
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Table 4.1: The eight genes each with a score of 4 or 5 and identified by TWAS or
2ScML to be associated with LDL.
Gene Chromosome p Best K2 pTWAS p2ScML Score
LDLRAP1 1 13 1 2.35e-05 1.15e-07 5
GNAI3 1 26 8 9.93e-06 7.11e-01 4
CCDC93 2 3 1 4.46e-03 3.39e-07 5
DDAH2 6 13 0 3.87e-06 3.87e-06 4
HP 16 14 1 3.31e-03 3.84e-08 4
CARM1 19 9 2 4.02e-06 1.24e-01 4
SMARCA4 19 3 1 1.01e-25 3.62e-08 4
LPAR2 19 6 1 1.80e-01 3.73e-10 4
notable that the following four genes with strong literature support for their relevance
to LDL were identified by our new method, but missed by the standard TWAS: both
genes LDLRAP1 and CCDC93 were reported to be associated with LDL [40, 13, 24];
gene HP was linked to diabetic nephropathy [2] and incidence of coronary artery
disease in type 1 diabetes [25]; gene LPAR2 was reported as a potential effector gene
for fatty liver [11].
Chapter 5
Conclusion and Discussion
We have proposed a Two-Stage Constrained Maximum Likelihood (2ScML) method
to draw inference on causal effects in the presence of invalid instruments. Here, in ad-
dition to allowing correlated and high-dimensional IVs, we allow the violation of some
or all of the three IV assumptions; our modeling assumptions are far more general
than many existing methods, such as the popular MR-Egger regression. Theoretical
and simulation results confirm the oracle property of 2ScML with superior perfor-
mance over the standard/naive 2SLS/TWAS, Two-Stage Hard Threshold (TSHT)
and MR-Egger regression. To meet the urgent need in current genetics research
(while overcoming some limitations of many existing robust IV methods that do not
apply to two-sample GWAS summary data), we have developed 2ScML for both one-
sample and two-sample cases and GWAS summary data, making it widely applicable
to identify causal genes in TWAS and infer causal relationships between pairs of
complex traits. We have applied 2ScML to a real dataset to discover causal genes for
LDL with GWAS summary data, leading to some encouraging results. More appli-
cations to other data and comparisons with other existing methods warrant future
investigation.
An R package implementing 2ScML with some example data, code and tutorials
is publicly available at https://github.com/xue-hr/2ScML.
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Appendix A
Proofs
Theorem 2. With Assumption 1 satisfied, the probability of the oracle esti-
mator β̂or defined in (2) being unique converges to 1 as n → ∞, and β̂or
is a consistent estimator of the true causal effect β0 with β̂or p−→ β0 as
n → ∞. Furthermore, we have
√
n(β̂or − β0) d−→ N(0, v), with variance
v = (σ21 + 2σ12β
0 + (β0)2σ22) · (Σ−1)11 − (2σ12β0 + (β0)2σ22) · (Σ−1ΨΣ−1)11. Under
the null hypothesis H0: β0 = 0, we have v = σ21 · (Σ−1)11. Here σ21, σ22, σ12 are
the variances and covariance of the error terms as defined in (1).
Proof. We can get γ̂orA = (ZTAZA)−1ZTAD and D̂ = PZAD = ZAγ0A + PZAξ. Note
that
||MZBD̂||2 = ||MZBZAγ0A + MZBPZAξ||2
≥||MZBZAγ0A||2/2− ||MZBPZAξ||2 ≥ n · d0/2− ||PZAξ||2
Since ξTPZAξ follows σ22 ·χ2|A|, P (||MZBD̂||2 > 0)→ 1. When ||MZBD̂||2 > 0, denote
X = (D̂,ZB), X has full column rank. Rewrite Y = β0D̂+ZBα0B+β0(I−PZA)ξ+ε.
Then, we obtain the unique oracle estimator:
(β̂or, α̂orB )
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Now we show XTX
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||, and ξTPZAξ ∼ σ22 ·χ2|A|,
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T (β0(I−PZA)ξ + ε)√
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n
d−→ Σ−1N(0,Π) = N(0,Σ−1ΠΣ−1).
Thus,
√

















Under the null hypothesis β0 = 0, σ2 = σ21 · (Σ−1)11.
It is somewhat surprising that the asymptotic variance v depends on β0 in view
of the results of Zhu et al. [4] and Windmeijer et al. [3], in which the asymptotic
variances are independent of β0. This is because Proposition 2 of Zhu et al. [4]
assumes that the error term ε is independent of the covariates, whereas Windmeijer
et al. [3] only considers relevant IVs without invalid IVs in their model, i.e. their set
A, must be a subset of all IVs in their model, although it has similar model setups as
ours. In particular, in (5) of Windmeijer et al. [3],
Y = β0 · D̂ + ZAα0A + ξ, (A.2)
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where ξ is defined implicitly. Actually, since their true model is
D = Zγ0 + v,
Y = β0 ·D + ZAα0A + ε,
and
D̂ = PZD = Zγ
0 + PZv.
We can rewrite
Y = β0 · D̂ + ZAα0A + ε+ β0(I−PZ)v,
so explicitly
ξ = ε+ β0(I−PZ)v. (A.3)






Plugging (A.2) into (A.4), we get
















However, since ZA is a subset of Z and I−PZ = MZ,
MZA(I−PZ) = I−PZ. (A.6)
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where the key is that ZA is a subset of Z in (A.6).
In contrast, in our model, the set of invalid IVs might not be a subset of the set
of relevant IVs, so (A.6) does not hold. This explains why our asymptotic variance v
depends on β. However, if the subset of invalid IVs (i.e. B) is a subset of all relevant
IVs (i.e. A), then in Theorem 2 yields that Σ = Ψ and our asymptotic variance v is
independent of β0.
Next, we present a lemma to be used in the proof of Theorem 3.
Lemma 1. For two vectors A,B ∈ Rn, if ||A||||B|| = k > 1, then the largest absolute
eigenvalue of PA+B −PA is no greater than 1k .
Proof. Let θ = AT ·B||A||·||B|| . Then |θ| ≤ 1. Define e1 =
A






||u2|| . Hence, ||e1|| = ||e2|| = 1 and e
T
1 · e2 = 0. Following the Gram-Schmidt
procedure, we generate e3, · · · , en, such that ||ei|| = 1, i = 1, · · · , n and eTi · ej = 0,
for i 6= j, 1 ≤ i, j ≤ n. Let Q = (e1, · · · , en) ∈ Rn×n, Q is orthonormal. Then,
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0 0 0 · · · 0

·QT .
So the non-zero eigenvalues of PA+B −PA are those of
D =







































Theorem 3. Under Assumptions 1 to 4, if K1 = |A| and K2 = p0, then
P
(
(β̂, α̂) = (β̂or, α̂or)
)
→ 1, either as n→∞ with a fixed p, or as n, p→∞.
Proof. By Assumption 1, it follows from Theorem 2 that the oracle estimator is
unique. By Assumptions 2 and 3, it follows from Theorem 3 of [2] that P (γ̂ =
γ̂or) → 1. Now we focus on the situation of γ̂ = γ̂or and D̂ = ZAγ0A + PZAξ. Let
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S(β,α) = ||Y − β · D̂ − Zα||2. Then,
I = P ((β̂, α̂) 6= (β̂or, α̂or))

















∣∣|αBc1 |≤τ}S(β,α) ≤ S(β̂or, α̂or)).
For each B1, we bound IB1 = P (min{α
∣∣|αBc1 |≤τ} S(β,α) ≤ S(β̂or, α̂or)). Towards
this end, let (β̂T , α̂T ) = argmin
{α
∣∣|αBc1 |≤τ} S(β,α). For a = n > 1,
S(β̂T , α̂T ) ≥ a− 1
a
||Y − D̂ · β̂T − ZB1α̂TB1||







2 − (a− 1) · p · cmaxτ 2.
Rewrite Y = D̂ ·β0 +ZBα0B +β0 · (I−PZA)ξ+ε. Subsequently, for simplicity, we
use notations ε = β0 · (I−PZA) · ξ + ε, Y = ZBα0B + ε since (I − PD̂∪ZB1 )D̂ = 0,




















Q = QTΛQ. (A.7)
Now,
S(β̂T , α̂T ) ≥a− 1
a
||(I−PZAγ0A∪ZB1 )Y ||




Y T (PZAγ0A∪ZB1 −PD̂∪ZB1 )Y ,
and
S(β̂or, α̂or) = ||(I−PZAγ0A∪ZB)ε||
2 + εT (PZAγ0A∪ZB −PD̂∪ZB)ε.
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So,
S(β̂T , α̂T )− S(β̂or, α̂or)
≥− 1
a
(ε− (a− 1)(I−PZAγ0A∪ZB1 )ZBα
0
B)
T (I−PZAγ0A∪ZB1 )(ε− (a− 1)(I−PZAγ0A∪ZB1 )ZBα
0
B)
+ (a− 1)||(I−PZAγ0A∪ZB1 )ZBα
0





Y T (PZAγ0A∪ZB1 −PD̂∪ZB1 )Y − ε











(ε− (a− 1)(I−PZAγ0A∪ZB1 )ZBα
0
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T (PZAγ0A∪ZB −PD̂∪ZB )ε,
b1 = (a− 1− δ)||(I−PZAγ0A∪ZB1 )ZBα
0
B ||2,
b2 = δ1||(I−PZAγ0A∪ZB1 )ZBα
0
B ||2 − (a− 1) · p · cmaxτ2,
b3 = δ2||(I−PZAγ0A∪ZB1 )ZBα
0
B ||2,
b4 = δ3||(I−PZAγ0A∪ZB1 )ZBα
0
B ||2.
So, IB1 ≤ P (L1 ≥ b1) + P (L2 ≥ b2) + P (L3 ≥ b3) + P (L4 ≥ b4). For simplicity, we
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0
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Here i = |B \ B1|. By Theorem 3 of [2] and Assumption 2,
∑
B1∈B P (L1 ≥ b1) → 0.
Similarly, by Assumption 2 and 3,
∑
B1∈B P (L2 ≥ b2)→ 0.
To prove that
∑
B1∈B P (L3 ≥ b3) → 0, note that L3 = 0 when A ⊆ B1.
So, ∑
B1∈B
P (L3 ≥ b3) =
∑
B1∈G
P (L3 ≥ b3).
Moreover, note that PZAγ0A∪ZB1 = PZB1 +Pu and PD̂∪ZB1 = PZB1 +Pu+v, where
u = MZB1ZAγ
0
A and v = MZB1PZAξ. So, PD̂∪ZB1 − PZAγ0A∪ZB1 = Pu+v − Pu.
Hence, for q = 1
3
,
P (L3 ≥ b3)










,Y T (Pu+v −Pu)Y ≥ b3).
By Lemma 1, P ( ||v||||u|| ≤
1
nq





Y TY ≥ b3) ≤
P ( 1
nq
Y TY ≥ b3). So





) + P (
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where C1 is a positive constant and i = |B \ B1|. By similar ar-









Y TY ≥ b3)→ 0 as n, p→∞.
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)→ 0 as n, p→∞.
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To show
∑
B1∈B P (L4 ≥ b4) → 0, note that PZA∪ZB − PZB = PU, where
U = MZBZA, so









































P (L4 ≥ b4) ≤C4 · e−
t
σ2
δ3ni(Cmin 2−d2σ2 log r),
where C4 is some positive constant and i = |B \ B1|. So,
∑
B1∈B P (L4 ≥ b4)→ 0, as
n, p→∞. This establishes that P ((β̂, α̂) 6= (β̂or, α̂or))→ 0, as n, p→∞.
Corollary 1. Assume that Assumptions 1 to 4 are met. If K1 = |A| and K2 = p0,
then under the null hypothesis of β0 = 0, Λn converges in distribution to χ21, a chi-
squared distribution with degrees of freedom 1, either as n→∞ with a fixed p, or as
both n, p→∞.
Proof. By Theorem 3, P ((β̂, α̂) 6= (β̂or, α̂or)) → 0. By Theorem 3 of [2], under the
null hypothesis, P (α̂(0)) 6= α̂or0 ))→ 0, where α̂or0 = argminα ||Y − ZBαB||2.








Hence, R(ε) → 0 as n → ∞. Then, it suffices to show that
εT (PD̂∪ZB −PZAγ0A∪ZB)ε→p 0.
Note that PZAγ0A∪ZB = PZB + Pu and PD̂∪ZB = PZB + Pu+v, where u = MZBZAγ
0
A
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and v = MZBPZAξ. So, PD̂∪ZB −PZAγ0A∪ZB = Pu+v −Pu. Moreover,
εT (Pu+v −Pu)ε =
εTuuTε+ εTvvTε+ 2εTuvTε






uTu+ vTv + 2uTv
− (v
Tv + 2uTv)εTuuTε
uTu(uTu+ vTv + 2uTv)
.
By Assumption 1, uTu
n
≥ d0 > 0. Note that vTv follows a χ2-distribution with
the degrees of freedom no greater than |A|. Hence, vT v
n
→p 0. Moreover, uTv
follows N(0, (γ0A)TZTAMZBPZAMZBZAγ0Aσ22), so
uT v
n



















Since εTv = εTMZBZA(ZTAZA)−1ZTAξ, (ZTAZA)−1ZTAξ follows N(0, (ZTAZA)−1). As
a result, (ZTAZA)−1ZTAξ →p 0. Finally, εTMZBZA follows N(0,ZTAMZBZA). So,
εT v√
n
→p 0. Consequently, εT (Pu+v −Pu)ε→p 0 as n→∞. Thus Λn →d χ21.
Theorem 4. Assume that Assumptions 1 to 4 are met. Then when p is fixed, if
|A| ∈ K1 and p0 ∈ K2, we have P
(
K̂1 = |A|, K̂2 = p0
)
→ 1 as n→∞.
Proof. To be clear, in the following of the proof we denote |A| = p1 and |B| = p0 = p2.




→ 1, which is equivalent to P (BIC1(K1) ≤ BIC1(p1))→
0 for any K1 6= p1. From Theorem 3, we have P (γ̂p1 = γ̂or) → 1, so P (||γ̂p1||0 =
p1)→ 1. So we have
BIC1(p1) = n · log
||D − Zγ̂p1||2
n
+ log(n) · ||γ̂p1||0
≤ n · log ||D − Zγ
0||2
n
+ log(n) · p1
= n · log ||ξ||
2
n
+ log(n) · p1.
Suppose for some A1 ⊆ S, |A1| = K1, and for i ∈ Ac1, | (γ̂K1)i | ≤ τ1. With Assumption
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3, following similar argument in proof of Theorem 3, we have
BIC1(K1) = n · log
||D − Zγ̂K1||2
n
+ log(n) · ||γ̂K1||0
≥ n · log ||D − ZA1(γ̂K1)A1||
2 − n · p · cmax · τ 21
n
+ log(n) ·K1













+ log(n) ·K1 ≤ n · log
||ξ||2
n






























































+ log(n) ·K1 ≤ n · log
||ξ||2
n
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for some positive constant C, and













When K1 > p1, we have ||MZA1D||
2 follows σ22χ2n−K1 , and
P (BIC1(K1) ≤ BIC1(p1)) = P
(















→ 1 as n→∞.








→ 1, we only need to
consider the case Â = A, thus D̂ = ZAγ0A + PZAξ. From Theorem 3, we have
P (α̂p2 = α̂
or)→ 1, so P (||α̂p2||0 = p2)→ 1. We have
BIC2(p2) = n · log
||Y − β̂p2 · D̂ − Zα̂p2||2
n
+ log(n) · p2
≤ n · log ||Y − β
0 · D̂ − Zα0||2
n
+ log(n) · p2
= n · log ||β
0 ·MZAξ + ε||2
n
+ log(n) · p2.
Suppose for some B1 ⊆ S, |B1| = K2 and | (α̂K2)Bc1 | ≤ τ2. With Assumption 3,
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following similar argument in proof of Theorem 3, we have
BIC2(K2) = n · log
||Y − β̂K2 · D̂ − Zα̂K2 ||2
n
+ log(n) · ||α̂K2||0
≥ n · log ||Y − β̂K2 · D̂ − ZB1(α̂K2)B1||
2 − n · p · cmaxτ 22
n
+ log(n) ·K2













+ log(n) ·K2 ≤ n · log
||β0 ·MZAξ + ε||2
n
+ log(n) · p2
)
.
With Assumption 4 and similar arguments in proof of Theorem 3, we get
P (BIC2(K2) ≤ BIC2(p2))




+ log(n) ·K2 ≤ n · log
||β0 ·MZAξ + ε||2
n
+ log(n) · p2)
= P (n · log
||MZAγ0A∪ZB1 (ZBα
0




≤ n · log ||β
0 ·MZAξ + ε||2
n
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so we have
P (BIC(K2) ≤ BIC(p2))










+ log(n) · (K2 − p2) ≤ n log






















||β0 ·MZAξ + ε||2
n




















for some positive constant C, thus
P (BIC2(K2) ≤ BIC2(p2))
=P
(
n · log(1 + C
σ21 + 2σ12β
0 + (β0)2σ22
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When K2 > p2,
P (BIC(K2) ≤ BIC(p2))
=P
(
log(n) · (K2 − p2) ≤ n · log
||β0 ·MZAξ + ε||2
||MZAγ0A∪ZB1 (ε+ β




log(n) · (K2 − p2) ≤ n · log
||β0 · ξ + ε||2 + ||β0 ·PZAξ||2 + 2β0 · ξTPZA(β0 · ξ + ε)
||MZAγ0A∪ZB1 (ε+ β



























→ 1 as n→∞.
Theorem 5. With Assumptions 1 and 5 satisfied, the probability of the ora-
cle estimator β̂or defined in (9) being unique converges to 1 as n, n2 → ∞,
and β̂or is a consistent estimator of true causal effect β0 with β̂or p−→ β0 as
n, n2 → ∞. Furthermore, we have
√
n(β̂or − β0) d−→ N(0, v), with variance
v = (σ21 + 2σ12β
0 + (β0)2σ22) · (Σ−1)11 + w(β0)2σ22(Σ−1Ψ2Σ−1)11. Under the null hy-
pothesis H0: β0 = 0, we have v = σ21 · (Σ−1)11.
Proof. Note that
||MZBD̂||2 = ||MZBZAγ0A + MZBZAe||2 ≥ ||MZBZAγ0A||2/2− ||MZBZAe||2 ≥ n · d0/2− ||ZAe||2.
Then, ||ZAe||2/n = eT (ZTAZA/n)e, since e
p−→ 0|A|×1,ZTAZA/n → UA as n, n2 → ∞.
Hence, P (||MZBD̂||2 > 0) → 1, which means the oracle estimator is unique with
probability tending to 1 as n→∞. Rewrite
Y = β0 · D̂ + ZBα0B + ε+ β0 · ξ − β0 · ZAe.
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Let X = (D̂,ZB) and X0 = (ZAγ0A,ZB). Now,β̂or
α̂orB
 = (XTX)−1XTY =
 β0
α0B






















(ZAγ0A + ZAe)T (ZAγ0A + ZAe) (ZAγ0A + ZAe)TZB
ZTB(ZAγ
0
























(ε+ β0ξ) ∼ N
(












Note that Θ = QΛQT , Q is orthonormal and Λ is diagonal. Let e∗ = QTe ∼














→ UA. Then as the eigenvalues of
ZTAZA
n









Note that n2Θ→ Θ0. Then the eigenvalues of Λ are upper-bounded by u2n2 . Thus,
√
nu1(e




































































→ Ψ2. A combination of (A.13), (A.16) and (A.17) yields

















Theorem 6. Under Assumptions 1, 3, 4, 5 and 6, if K2 = p0, then
P
(
(β̂, α̂) = (β̂or, α̂or)
)
→ 1, either as n→∞ with a fixed p, or as both n, p→∞.
Proof. By Assumption 1 and 5, it follows from Theorem 5 that the oracle estimator
is unique. So
I = P ((β̂, α̂) 6= (β̂or, α̂or))

















∣∣|αBc1 |≤τ}S(β,α) ≤ S(β̂or, α̂or)).
For each B1, we bound IB1 = P (min{α
∣∣|αBc1 |≤τ} S(β,α) ≤ S(β̂or, α̂or)). For a =
n > 1, we have
S(β̂T , α̂T ) ≥ a− 1
a
||Y − D̂ · β̂T − ZB1α̂TB1||







2 − (a− 1) · p · cmaxτ 2,
where (β̂T , α̂T ) = argmin
{α
∣∣|αBc1 |≤τ} S(β,α). Rewrite Y = β0 · D̂ + ZBα0B + ε+ β0 ·
ξ− β0 ·ZAe. For simplicity, subsequently, we use notations ε = ε+ β0 · ξ− β0 ·ZAe,
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Y = ZBα
0







I + (β0)2σ22 · ZAΘZTA = QTΛQ.










upper-bounded by u1. Note that the eigenvalues of Θ are upper-bounded by u2n2 and
n
n2
is upper-bounded by u3. So, the eigenvalues of Λ are between σ2m = σ21 + 2σ12β0 +
σ22(β








2 − (a− 1) · p · cmaxτ2 +
a− 1
a
Y T (PZAγ0A∪ZB1 −PD̂∪ZB1 )Y .
Then,
S(β̂or, α̂or) = ||(I−PZAγ0A∪ZB)ε||
2 + εT (PZAγ0A∪ZB −PD̂∪ZB)ε.
So,
S(β̂T , α̂T )− S(β̂or, α̂or)
≥− 1
a
(ε− (a− 1)(I−PZAγ0A∪ZB1 )ZBα
0
B)
T (I−PZAγ0A∪ZB1 )(ε− (a− 1)(I−PZAγ0A∪ZB1 )ZBα
0
B)
+ (a− 1)||(I−PZAγ0A∪ZB1 )ZBα
0





Y T (PZAγ0A∪ZB1 −PD̂∪ZB1 )Y − ε
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(ε− (a− 1)(I−PZAγ0A∪ZB1 )ZBα
0
B)











T (PZAγ0A∪ZB −PD̂∪ZB )ε,
b1 = (a− 1− δ)||(I−PZAγ0A∪ZB1 )ZBα
0
B ||2,
b2 = δ1||(I−PZAγ0A∪ZB1 )ZBα
0
B ||2 − (a− 1) · p · cmaxτ2,
b3 = δ2||(I−PZAγ0A∪ZB1 )ZBα
0
B ||2,
b4 = δ3||(I−PZAγ0A∪ZB1 )ZBα
0
B ||2.
So, IB1 ≤ P (L1 ≥ b1)+P (L2 ≥ b2)+P (L3 ≥ b3)+P (L4 ≥ b4). For simplicity, we use







. Let v = Q(a − 1)(I − PZAγ0A∪ZB1 )ZBα
0
B,
P = Q(PZAγ0A∪ZB1 )Q
T . Then,









(ε− v)T (I−P)(ε− v)
)















(ε− v)T (I−P)(ε− v)
)
























(Cmin − d2σ2 log r)
)
,
where i = |B \B1|. By Theorem 3 of [2] and Assumption 2,
∑
B1∈B P (L1 ≥ b1)→ 0.
Similarly, by Assumption 3,
∑
B1∈B P (L2 ≥ b2)→ 0.
Appendix A. Proofs 63
Now,
∑
B1∈B P (L3 ≥ b3)→ 0. Note that L3 = 0 when A ⊆ B1. So,
∑
B1∈B
P (L3 ≥ b3) =
∑
B1∈G
P (L3 ≥ b3).
Hence, PZAγ0A∪ZB1 = PZB1 +Pu, here u = MZB1ZAγ
0
A; and PD̂∪ZB1 = PZB1 +Pu+v,




P (L3 ≥ b3)










,Y T (Pu+v −Pu)Y ≥ b3).
By Lemma 1, P ( ||v||||u|| ≤
1
nq





Y TY ≥ b3) ≤
P ( 1
nq
Y TY ≥ b3). So,





) + P (
1
nq
Y TY ≥ b3).
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where C1 is a positive constant and i = |B \ B1|. By simi-









Y TY ≥ b3)→ 0 as n, p→∞.
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3 (Cmin 2 −
1
t












)→ 0 as n, p→∞.
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To show that
∑
B1∈B P (L4 ≥ b4) → 0, note that PZA∪ZB − PZB = PU, where
U = MZBZA. Hence,









































P (L4 ≥ b4) ≤ C4 · e−
t
σ2
δ3ni(Cmin 1−d2σ2 log r),
where C4 is a positive constant and i = |B \B1|. So, we have
∑
B1∈B P (L4 ≥ b4)→ 0,
as n, p → ∞. Thus we have proved that P
(
(β̂, α̂) = (β̂or, α̂or)
)
→ 1 as n, p →
∞.
Corollary 2. Assume that Assumptions 1, 3, 4, 5 and 6 are met. If K2 = p0, then
under the null hypothesis of β0 = 0, Λn converges in distribution to χ21, a chi-squared
distribution with degrees of freedom 1, either as n → ∞ with a fixed p, or as both
n, p→∞.
Proof. By Theorem 6, P ((β̂, α̂) 6= (β̂or, α̂or)) → 0. By Theorem 3 of [2], under the
null hypothesis, P (α̂(0)) 6= α̂or0 ))→ 0, where α̂or0 = argminα ||Y − ZBαB||2.








Hence, R(ε) → 0 as n → ∞. Then, it suffices to show that
εT (PD̂∪ZB −PZAγ0A∪ZB)ε→p 0.
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Note that PZAγ0A∪ZB = PZB + Pu and PD̂∪ZB = PZB + Pu+v, where u = MZBZAγ
0
A
and v = MZBZAe. So, PD̂∪ZB −PZAγ0A∪ZB = Pu+v −Pu. Moreover,
εT (Pu+v −Pu)ε =
εTuuTε+ εTvvTε+ 2εTuvTε






uTu+ vTv + 2uTv
− (v
Tv + 2uTv)εTuuTε
uTu(uTu+ vTv + 2uTv)
.
By Assumption 1, uTu
n
≥ d0 > 0. Since e ∼ N(0, σ22Θ) and n2Θ → Θ0, we
have vT v
n

























→p 0. Consequently, εT (Pu+v − Pu)ε →p 0 as
n→∞. Thus Λn →d χ21.
Theorem 7. Assume that Assumptions 1, 3, 4, 5 and 6 are met. Then when p is




→ 1 as n→∞.
Proof. It is sufficient to show P (BIC(K2) ≤ BIC(p0)) → 0 for any K2 6= p0. From
Theorem 6, we have P (α̂p0 = α̂or)→ 1, so P (||α̂p0||0 = p0)→ 1. We have
BIC(p0) = n · log
||Y − β̂p0 · D̂ − Zα̂p0||2
n
+ log(n) · ||α̂p0||0
≤ n · log ||Y − β
0 · D̂ − Zα0||2
n
+ log(n) · p0
= n · log ||ε+ β
0ξ + β0ZAe||2
n
+ log(n) · p0,
here e = γ0A−γ̂A ∼ N(0, σ22Θ), and ||e||2 = op(1) by Assumption 5. Suppose for some
B1 ⊆ S, |B1| = K2 and | (α̂K2)Bc1 | ≤ τ2, with Assumption 3 and similar arguments
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in proof of Theorem 6, we have
BIC(K2) = n · log
||Y − β̂K2 · D̂ − Zα̂K2||2
n
+ log(n) · ||α̂K2||0
≥ n · log ||Y − β̂K2 · D̂ − ZB1(α̂K2)B1||
2 − n · p · cmaxτ 22
n
+ log(n) ·K2













+ log(n) ·K2 ≤ n · log
||ε+ β0ξ + β0ZAe||2
n
+ log(n) · p0
)
.
Since ||e||2 = op(1), and D̂ = ZAγ0A−ZAe, with Assumption 4 and similar arguments
in proof of Theorem 6, we get
P (BIC(K2) ≤ BIC(p0))




+ log(n) ·K2 ≤ n · log
||ε+ β0ξ||2
n
+ log(n) · p0)
= P (n · log
||MZAγ0A∪ZB1 (ZBα
0




≤n · log ||ε+ β
0ξ||2
n




B + ε+ β
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P (BIC(K2) ≤ BIC(p0))









+ op(1)) + log(n)K2










































for some positive constant C, thus
P (BIC(K2) ≤ BIC(p0))
=P
(









Appendix A. Proofs 70
When K2 > p0, we have
P (BIC(K2) ≤ BIC(p0))
≤P
(
log(n) · (K2 − p0) ≤ n · log
||ε+ β0ξ||2
||MZAγ0A∪ZB1 (ε+ β




















→ 1 as n→∞.
Appendix B
Consistent Estimation of the
Asymptotic Variances
B.1 One-Sample Case
B.1.1 Estimating v with the Oracle Estimators
For the purpose of presentation, we first consider estimating the asymptotic variance

















Since γ̂orA = γ0A + (ZTAZA)−1ZTAξ and (ZTAZA)−1ZTAξ
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as n → ∞. Plug in these consistent estimates, we obtain consistent estimators of Σ
and Ψ as
Σ̂or =






 /n p−→ Σ,
Ψ̂or =






 /n p−→ Ψ.
(B.1)
To estimate (σ21 + 2σ12β0 + (β0)2σ22), let D̂or = ZAγ̂orA and X = (D̂or,ZB). Then,
Ŷ or = β̂or · D̂or + ZBα̂orB = PXY .
Let
v̂or1 =





(I−PX) (β0(I−PZA)ξ + ε)
n
.





p−→ σ21 + 2σ12β0 + (β0)2σ22.
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Next, we estimate σ21. Let X∗ = (D,ZB) and
Ŷ or∗ = β̂
or ·D + ZBα̂orB ,
we have







||Y − Ŷ or∗ ||2
n
.
Note that XTX/n p−→ Σ, εTX∗/n p−→ 0, εTε/n p−→ σ21. By (A.1), we have
v̂or2
p−→ σ21. (B.3)
Combining (B.1), (B.2) and (B.3) yields a consistent estimator v̂or of v in Theorem
1 as follows:






B.1.2 Estimating v with the 2ScML Estimators
In practice, since the Oracle estimators are unknown, we estimate v using the 2ScML
estimators γ̂, β̂ and α̂. Let Â = {i
∣∣γ̂i 6= 0, 1 ≤ i ≤ p} and B̂ = {j∣∣α̂j 6= 0, 1 ≤ j ≤ p}.
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Let D̂ = ZÂγ̂Â. Then
Ŷ = β̂ · D̂ + ZB̂α̂B̂.
Now, we replace v̂or1 by
v̂1 =




Ŷ∗ = β̂ ·D + ZB̂α̂B̂.





A combination of (B.4), (B.5) and (B.6) yields that






By Theorem 2, P (γ̂ = γ̂or) → 1, P
(
(β̂, α̂) = (β̂or, α̂or)
)
→ 1, P (Â = A) → 1, and
P (B̂ = B)→ 1. Thus, P (v̂ = v̂or)→ 1, implying that v̂ p−→ v.
B.2 Two-Sample Case
B.2.1 Estimating v with the Oracle Estimators
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As in the one-sample case, let D̂ = ZAγ̂A and X = (D̂,ZB). Then,
Ŷ or = β̂or · D̂ + ZBα̂orB = PXY ,
v̂or1 =








Given the second sample of size n2, some consistent estimators Θ̂0 and σ̂22 of Θ0 and
σ22 can be obtained, for example, by linear regression. As in the one-sample case, Σ̂or










 Θ̂0 (ZTAZAγ̂A/n ZTAZB/n) p−→ Ψ2.
In (Appendix B.2.1), we estimate w by n/n2 and β0 by β̂or. Finally, v̂or of v can be
written as











B.2.2 Estimating v with the 2ScML estimators
Since the Oracle estimators are unknown in practice, we estimate v with the 2ScML
estimators β̂ and α̂. Similar to the one-sample case, in v̂or, we replace β̂or, α̂or
and B with β̂, α̂ and B̂ respectively, to obtain v̂. By Theorem 5, we have
P
(
(β̂, α̂) = (β̂or, α̂or)
)
→ 1, and P (B̂ = B) → 1, implying P (v̂ = v̂or) → 1, and
thus a consistent estimator v̂ p−→ v.
Appendix C
More Simulation Results
C.1 Full Simulation 1 Results: One-Sample Case
with IV Assumptions (A) and (C) Violated
We compared 2ScML with TSHT, naive-2SLS, and oracle-2SLS through simulations,
and the simulation setups closely followed those of TSHT [1]. First we compared the
Type-I Errors of these methods. In Setup 1, we set the number of IVs p = 100, and
the sample size n varying at 100, 200, 300, 1000 and 2500. Instruments Z’s followed a
multivariate normal distribution with mean 0 and an AR(0.5) covariance matrix Σ:
Σi,j = 0.5
|i−j| for 1 ≤ i, j ≤ p. The error terms (ε, ξ) were generated from a bivariate
normal distribution with mean 0, variance 1.5 and covariance 0.75. For 2 ≤ i ≤ 8,
γ0i = 0.5; otherwise γ0i = 0; i.e. the 2nd to 8th IVs were relevant and had an equal effect
size 0.5. For i = 7, 8, α0i = 0.5; otherwise α0i = 0; i.e. the 7th and 8th instruments
were invalid IVs and had some direct effects on the outcome. When β0 = 0, there
was no causal effect from the exposure to outcome, i.e. the null case. Setup 2 was the
same as Setup 1 except: for i = 1, 7, 8, 9, α0i = 0.5; otherwise α0i = 0; i.e. the relevant
7th and 8th instruments were invalid, and the irrelevant 1st and 9th instruments were
also invalid.
For both setups, in each simulation we generated n samples from the model in (1),
76
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Figure C.1: Empirical Type-I Error Rates of Setup 1 and Setup 2: the x-axis shows
the sample size, while y-axis shows the empirical Type-I Error rates based on 1000







































































Setup 2: Type−I Error
then we applied the four methods to simulated data to test H0 : β0 = 0 versus H1 :
β0 6= 0. For 2ScML, in stage 1 we used BIC to choose the best K1 ∈ {5, 6, 7, 8, 9, 10};
in stage 2 we used BIC to choose the best K2 ∈ {0, 1, 2, 3, 4, 5}; and we set τ1 = τ2 =
1 × 10−5. For the naive-2SLS, in stage 1 we used the 2nd to 8th IVs to get D̂, then
in stage 2 we fitted a linear regression model of Y on D̂. The oracle-2SLS had the
same stage 1 as the naive-2SLS, but in stage 2 we fitted a linear regression model of
Y on D̂ and the 7th and 8th IVs for Setup 1, or D̂ and the 1st, 7th, 8th and 9th IVs for
Setup 2; in other words, we included the 2 and 4 invalid IVs for Setup 1 and Setup 2
respectively.
For each setup, we repeated the simulation 1000 times and set the nominal signif-
icant level at 0.05 for each n; Figure C.1 shows the simulation result. We can see that
the oracle-2SLS could always have a Type-I Error rate around the nominal level 0.05,
while naive-2SLS had a Type-I Error rate dramatically inflated around 1. When the
sample size was small, TSHT and 2ScML both had large Type-I Error rates. But as
the sample size increased from 100 to 300, the Type-I Error rate of 2ScML decreased
fast, while that of TSHT still had a relatively large Type-I Error. When the sample
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Figure C.2: Empirical Power Rates of Setup 1 and Setup 2: the x-axis shows the
causal effect size β0, while y-axis shows the empirical power rate based on 1000
simulations; the horizontal dashed line represents the nominal level 0.05.
















































































size was large enough, both TSHT and 2ScML could control their Type-I Error rate
satisfactorily around 0.05.
From Figure C.1 we can see that when the sample size was 2500, 2ScML, TSHT
and oracle-2SLS could control their Type-I Error rates. So we compared their power
at the sample size 2500, and in both setups we changed β0 from −0.5 to 0.1 with a
step size of 0.02. Then we applied all 4 methods and repeated the simulation 1000
times to calculate their empirical power. Figure C.2 shows the results with the x-axis
representing value of β0. Again, when β0 = 0, i.e. with no causal effect, 2ScML,
TSHT and oracle-2SLS could control Type-I Error at 0.05, while naive-2SLS had a
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Table C.1: Empirical type I error rates (for β0 = 0) and power (for β0 6= 0) of the
methods in Simulation 1.
β0
Setup 1 Setup 2
oracle-2SLS 2ScML TSHT oracle-2SLS 2ScML TSHT
-0.10 1.000 0.998 0.999 1.000 0.998 0.999
-0.08 1.000 0.998 0.998 1.000 0.998 0.998
-0.06 0.980 0.973 0.911 0.968 0.963 0.911
-0.04 0.746 0.738 0.572 0.720 0.705 0.571
-0.02 0.246 0.239 0.180 0.226 0.221 0.180
0.00 0.041 0.049 0.052 0.045 0.048 0.052
0.02 0.259 0.271 0.258 0.232 0.239 0.258
0.04 0.742 0.754 0.701 0.706 0.710 0.700
0.06 0.970 0.973 0.941 0.956 0.957 0.941
0.08 0.998 0.997 0.997 0.998 0.997 0.997
0.10 1.000 0.999 0.999 1.000 1.000 0.999
Type-I Error inflated to 1. In both Setups 1 and 2, when |β0| was large, 2ScML,
TSHT and oracle-2SLS all had power 1. When |β0| was small, the power of 2ScML
and that of oracle-2SLS were very close, and typically higher than that of TSHT.
Table C.1 shows the power of 2ScML, TSHT and oracle-2SLS for −0.1 ≤ β0 ≤ 0.1.
This supports the theory that 2ScML has the oracle property while TSHT does not.
We can see that, for the range −0.3 < β0 < −0.22 in Setup 1, naive-2SLS had power
smaller than 1, while the other three methods had power 1. This was not surprising:
the direct effects γ0 and α0 were positive, and the total effect of IVs on Y was
(β0 ·γ0 +α0), so negative β0 in a certain range would diminish the total effect toward
0 and decrease the power of naive-2SLS. We can see the similar pattern in Setup 2,
while the range was −0.42 < β0 < −0.32 with larger absolute values as compared to
−0.3 < β0 < −0.22 in Setup 1. The reason was that we had two more invalid IVs,
the 1st and 9th SNPs, with positive direct effects on Y , so it took negative β0 with
larger absolute values to cancel out the total effect.
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C.2 Simulation 3: Setups Mimicking Real Data
We did simulations with some realistic setups to mimic real data applications. We
first performed 2ScML to study the causal effect of gene GEMIN7 on chromosome 19
on Alzheimer’s disease (AD) and generated simulated data using the estimated pa-
rameters and real SNP data. More specifically, from the TWAS Fusion database, 366
SNPs from position 45092942 to 46094597 on chromosome 19 were used to estimate
the expression level of GEMIN7; then from the Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) database, we obtained the individual-level genotype data, i.e. values
of SNPs, and the outcome indicating the AD status for 785 individuals. We ex-
tracted all SNPs from 44992000 to 46195000 on chromosome 19 from the ADNI data,
i.e. by roughly extending 100kb up- and down-stream the gene region. After cleaning
and pruning out SNPs to make their pairwise correlations less than 0.6, we had 253
SNPs left. Among these 253 SNPs, 42 overlapped with the 366 SNPs with non-zero
estimated coefficients in the TWAS Fusion database, and 10 of them had the abso-
lute values of their estimated coefficients larger than 0.003 as shown in Table C.2.
We used these 42 SNPs with their TWAS Fusion estimated coefficients to predict
gene-expression levels in the first stage. In the second stage, we applied 2ScML: we
included the predicted gene-expression and all 253 SNPs; using cross-validation we
chose the best K2 as 3. The 3 chosen SNPs with their estimated coefficients were:
rs8100875 (position 45007076, coefficient -0.16), noRSname (position 45386467, coef-
ficient 0.12), rs2288918 (position 45528799, coefficient 0.10). We show the correlations
between these 3 SNPs and the 10 SNPs relevant to the expression level of GEMIN7
in Table C.2.
We then generated the simulated data accordingly. We used the real genotypes of
the 253 SNPs from the 785 individuals in ADNI, so we had the number of instruments
as p = 253 and the sample size n = 785 for each simulated dataset. From the
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Table C.2: Ten relevant IVs/SNPs on chromosome 19 used to generate exposure D,
and their correlations with invalid IVs/SNPs rs8100875, noRSname and rs2288918.









rs17658470 45115393 -0.00356 -0.0541 -0.0116 0.00677
rs2965164 45202052 -0.00471 -0.0183 -0.127 -0.0594
rs10421830 45210634 -0.00393 0.0639 -0.099 -0.00137
rs10405693 45326664 -0.00434 -0.0297 0.202 0.0431
rs440277 45361224 0.00972 0.0578 -0.000728 -0.0641
rs283814 45389224 0.00319 -0.00327 -0.147 -0.0438
rs10405859 45602781 0.0184 0.0204 -0.135 -0.283
rs238419 45853413 0.0103 0.0280 0.0241 -0.0150
rs8099878 46019601 -0.0119 -0.0194 0.0487 0.0801
rs8111589 46034558 -0.00384 0.0495 0.0398 0.138
TWAS Fusion website, the proportion of the variance of the expression level for gene
GEMIN7 explained by SNPs was about 10%. We had var(−0.0035 × rs17658470 +
· · ·+−0.0038× rs8111589) = 0.000436, so we generated ξ from a normal distribution
with mean 0 and variance 0.004. In stage 1 we generated exposure D with model of
(1) using 10 SNPs with their coefficients shown in Table C.2 and ξ. The proportion
of variance of outcome Y explained by 3 SNPs was around 10%, and var(−0.16 ×
rs8100875 + 0.12× noRSname+ 0.10× rs2288918) = 0.014, so we generated ε from
a normal distribution with mean 0 and variance 0.12, and set its correlation with ξ
as 0.2. For Setup 1, in stage 2 we generated Y from the model in (1) using generated
D, the 3 invalid IVs/SNPs, and ε. The direct effects α’s of these 3 SNPs were -0.16,
0.12, 0.10 respectively, and the causal effect β of D was one of values at -2, -1, -0.5,
-0.4, -0.3, -0.2, -0.1, 0, 0.1, 0.2, 0.3, 0.4, 0.5, 1 and 2. For Setup 2, in stage 2 we
excluded the 3 invalid IVs/SNPs while other aspects remained the same as in Setup
1, so we had 10 SNPs relevant to D and all SNPs were valid.
The setups of generating simulated data are shown in Figure C.3, where we only
mark out cor(rs10405693, noRSname) = 0.202 and cor(rs10405859, rs2288918) =
−0.283 because these two correlations were most significant. It is noted that besides
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these two correlations, there existed correlations (due to linkage disequilibrium) be-
tween the 10 SNPs relevant to D and 3 invalid SNPs having direct effects on Y as
shown in Table C.2. With Setup 1, for each β we did the simulation 1000 times
and calculated the proportion of p-values less than 0.05. We compared three meth-
ods: the naive-2SLS, oracle-2SLS and 2ScML. For all three methods, we used the
10 SNPs to get D̂ in stage 1. For 2ScML, in stage 2 we included all 253 SNPs, set
τ2 = 1×10−5, and used 5-fold cross-validation to choose the best K2 from 0 to 6. For
the naive-2SLS, in stage 2 we performed linear regression of Y on D̂; for the oracle-
2SLS, in stage 2 we performed linear regression of Y on D̂, rs8100875, noRSname
and rs2288918. Figure C.4 shows the empirical Type-I Error rates when β = 0, and
power when β 6= 0 from 1000 simulations.
In Figure C.4, the dashed horizontal black line is y = 0.05. When β = 0, it was
the null case. We can see that at this setting, both 2ScML and oracle-2SLS could
control the Type I Error rate at 0.05, but the naive-2SLS had an inflated Type I
Error rate around 45%. As the absolute value of β increased, the power of 2ScML
and oracle-2SLS increased. We observe that as β increased from 0 to 1, the power of
the naive-2SLS decreased, which was due to the reason as we explained for Figure C.2;
here a positive value of β in the range of 0 to 1 would diminish the total effect of the
SNPs on Y and thus decrease the power of the naive-2SLS.
In Setup 2, the naive-TWAS was identical to the oracle-2SLS. For each of β, we
did the simulation 1000 times and calculated the proportion of p-values less than
0.05. We compared two methods: oracle-2SLS and 2ScML. For both methods, we
used the 10 SNPs to get D̂ in stage 1. For 2ScML, in stage 2 we included all 253
SNPs, set τ2 = 1× 10−5, and used 5-fold cross-validation to choose the best K2 from
0 to 6. For oracle-2SLS, in stage 2 we performed linear regression of Y on D̂ only.
Figure C.5 shows the Type-I Error rate when β = 0, and power when β 6= 0 from the
simulations.
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(b) Setup 2 with all IVs being valid.
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In Figure C.5, the dashed horizontal black line is y = 0.05. When β = 0 it was
the null case. We can see in Setup 2, both 2ScML and oracle-2SLS could control the
Type I Error rate at 0.05, and they performed similarly with almost the same power.
Appendix D
Real Data Example: More Results
Here we show the details of the 32 significant genes identified by TWAS and 2ScML
in Table D.1.
Next we show the full literature search results for these 32 genes.
LDLRAP1 on Chromosome 1: LDLRAP1 is a liver-enriched gene that
plays a critical role in facilitating the removal of LDL from the circulatory system
[5, 6].
PIGV on Chromosome 1: From GWAS Catalog, PIGV has been reported
as associated with LDL and HDL [7]. PIGV is a mannosyltransferase that plays a
role in multiple cellular processes, including protein sorting and signal transduction
[8]. And Glycosylphosphatidylinositol (GPI) is a complex glycolipid that anchors
many proteins to the cell surface. The biosynthetic pathway of GPI is mediated by
sequential addition of sugars and other components to phosphatidylinositol. PIGV
adds the second mannose to the GPI core[9].
DOCK7 on Chromosome 1: From GWAS Catalog, genetic variants mapped to
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Table D.1: The 32 significant genes associated with LDL identified by TWAS or/and
2ScML with their literature search support scores (Score) and corresponding refer-
ences (Refs). The p-values less than the significance cut-off 0.05/4580 are marked
red.
Gene Chr p Best K2 pTWAS p2ScML Score Refs
LDLRAP1 1 13 1 2.35e-05 1.15e-07 5 [5], [6]
PIGV 1 5 1 6.58e-04 2.34e-06 3 [7], [8], [9]
DOCK7 1 13 0 7.64e-17 7.64e-17 3 [10]
PSRC1 1 19 5 8.40e-99 2.55e-75 3 [10]
PSMA5 1 13 6 1.12e-07 1.02e-03 2 [11], [12]
GNAI3 1 26 8 9.93e-06 7.11e-01 4 [13]
GSTM4 1 42 4 3.82e-06 9.65e-02 1 [14]
CCDC93 2 3 1 4.46e-03 3.39e-07 5 [15], [16], [17], [18]
MKRN2 3 12 0 4.92e-08 4.92e-08 2 [19]
RAF1 3 7 1 3.00e-04 8.63e-07 2 [20], [12]
PARP9 3 9 0 1.02e-06 1.02e-06 2 [16]
AIF1 6 15 1 1.20e-03 4.10e-06 2 [21], [22], [23]
DDAH2 6 13 0 3.87e-06 3.87e-06 4 [24], [25]
NOTCH4 6 18 1 1.13e-03 1.49e-06 2 [26], [21], [22]
TAP2 6 23 1 1.43e-03 4.37e-07 2 [27], [28], [29]
DDX56 7 9 2 6.46e-06 6.70e-02 3 [30], [19]
TMED4 7 11 1 7.06e-09 6.03e-04 0 NA
PARP10 8 4 0 1.35e-10 1.35e-10 3 [30]
GRINA 8 5 0 8.26e-11 8.26e-11 0 NA
FADS1 11 15 1 5.87e-14 2.85e-01 3 [26]
SH2B3 12 11 0 3.07e-10 3.07e-10 3 [31], [32], [33], [30], [34]
OASL 12 25 1 4.37e-08 1.22e-12 3 [35], [36], [37], [35]
HP 16 14 1 3.31e-03 3.84e-08 4 [16], [38], [39]
DHX38 16 10 3 4.33e-04 5.19e-09 3 [22], [40], [41], [42], [43]
TBKBP1 17 3 0 4.86e-06 4.86e-06 2 [16], [44]
KRI1 19 15 4 2.60e-01 2.49e-13 3 [30]
CARM1 19 9 2 4.02e-06 1.24e-01 4 [30], [45], [46], [47], [48]
SMARCA4 19 3 1 1.01e-25 3.62e-08 4 [16], [32], [49], [50]
LPAR2 19 6 1 1.80e-01 3.73e-10 4 [51]
PVRL2 19 11 4 1.24e-11 1.38e-05 3 [52], [53], [54], [55]
TOMM40 19 28 10 8.83e-36 3.48e-15 3 [56], [57], [58]
MAFB 20 4 1 5.76e-06 7.03e-01 3 [26], [59], [16]
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this gene are shown associated with LDL, TG, TC [10].
PSRC1 on Chromosome 1: From GWAS Catalog, genetic variants mapped to
this gene are shown associated with LDL, TC [10].
PSMA5 on Chromosome 1: From GWAS Catalog, PSMA5 has been re-
ported as associated with Intelligence [11], and Body Mass Index [12].
GNAI3 on Chromosome 1: GNAI3 participates in the development of
NAFLD in both cellular and mouse models [13].
GSTM4 on Chromosome 1: It is reported that a polymorphism in the
GSTM4 gene implicated lung cancer risk [14].
CCDC93 on Chromosome 2: From GWAS Catalog, CCDC93 has been
reported as associated with Venous thromboembolism [15], Triglycerides [16],
Cognitive performance [17]. Also, [18] provides evidence that a common variant in
CCDC93, encoding a protein involved in recycling of the LDLR, is associated with
lower LDL-c levels, lower risk of myocardial infarction and cardiovascular mortality.
MKRN2 on Chromosome 3: From [19], MKRN2 is associated with sys-
tolic blood pressure, red cell distribution width, and eosinophil counts.
RAF1 on Chromosome 3: From GWAS Catalog, RAF1 has been reported
as associated with cardiac hypertrophy [20], waist-to-hip ratio adjusted for BMI [12].
PARP9 on Chromosome 3: From GWAS Catalog, PARP9 has been re-
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ported as associated with total cholesterol levels [16]
AIF1 on Chromosome 6: From GWAS Catalog, AIF1 has been reported
as associated with metabolite levels [21], Blood protein levels [22]. And SNP
rs2844479 in AIF1 contributes to obesity risk in the Greek population [23].
DDAH2 on Chromosome 6: Asymmetric dimethylarginine (ADMA), present in
human serum, is an endogenous inhibitor of nitric oxide synthase and contributes to
vascular disease. Genetic variation in DDAH2 gene is significantly associated with
serum ADMA levels in participants with type 2 diabetes [24]. And hypermethylation
in DDAH2 promoter is positively correlated to the dysfunction of endothelial
progenitor cells (EPCs) in CAD patients [25].
NOTCH4 on Chromosome 6: From GWAS Catalog, NOTCH4 has been
reported as associated with triglycerides [26], metabolite levels [21], blood protein
levels [22].
TAP2 on Chromosome 6: From GWAS Catalog, TAP2 has been reported
as associated with diastolic blood pressure [27], type 1 diabetes and autoimmune
thyroid diseases [28], serum complement C3 and C4 levels [29].
DDX56 on Chromosome 7: From GWAS Catalog, DDX56 has been re-
ported as associated with LDL and TC [30], and cardiovascular disease [19].
TMED4 on Chromosome 7: Have not found any related study about this
gene.
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PARP10 on Chromosome 8: From GWAS Catalog, PARP10 has been re-
ported as associated with LDL and TC [30].
GRINA on Chromosome 8: Have not found any related study about this
gene.
FADS1 on Chromosome 11: From GWAS Catalog, FADS1 has been re-
ported as associated with LDL and TC [26].
SH2B3 on Chromosome 12: From GWAS Catalog, SH2B3 has been re-
ported as associated with blood pressure [31], coronary heart disease [32], blood
metabolite levels [33], LDL, HDL and TC [30]. And it is involved in blood diseases,
autoimmune disorders, and vascular disease [34].
OASL on Chromosome 12: From GWAS Catalog, OASL has been reported as
associated with cardiovascular disease risk factors [35], type 2 diabetes [36], serum
metabolite levels [37]. And OASL showed effects on gamma glutamyltransferase,
LDL and C-reactive protein [35].
HP on Chromosome 16: From GWAS Catalog, HP has been reported as
associated with LDL, HDL, TC [16]. And HP is linked to diabetic nephropathy [38],
and incidence of coronary artery disease in type 1 diabetes [39].
DHX38 on Chromosome 16: From GWAS Catalog, DHX38 has been re-
ported as associated with blood protein levels [22], interaction between LDL and
sleep [40], coronary artery disease [41], serum metabolite levels [42]. And from [43],
DHX38 is related to pig growth rate.
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TBKBP1 on Chromosome 17: From GWAS Catalog, TBKBP1 has been
reported as associated with HDL [16], body mass index [44].
KRI1 on Chromosome19: From GWAS Catalog, KRI1 has been reported
as associated with LDL and TC [30].
CARM1 on Chromosome 19: From GWAS Catalog, CARM1 has been re-
ported as associated with LDL and TC [30], C-reactive protein levels [45]. And
C9orf72-CARM1 axis in the control of stress-induced lipid metabolism and implicates
epigenetic dysregulation in relevant human diseases [46]. [47] shows that CARM1
promotes adipocyte differentiation by coactivating PPARγ-mediated transcription
and thus might be important in energy balance. [48] shows that increased CARM1
expression in type 2 diabetes suggests that epigenetic mechanisms are altered in
human diabetes.
SMARCA4 on Chromosome 19: From GWAS Catalog, SMARCA4 has
been reported as associated with LDL and TC [16], coronary heart disease [32],
peripheral artery disease [49]. And [50] suggests that SMARCA4 polymorphism may
conducive to play a protective role against the hypertension risk.
LPAR2 on Chromosome 19: [51] supports LPAR2 as a potential effector
gene in the fatty liver NCAN locus.
PVRL2 on Chromosome 19: From GWAS Catalog, AC011481.2, which is
antisense to PVRL2, has been reported as associated with body fat percentage [52],
type 2 diabetes [53], LDL and TG[54], body mass index [55].
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TOMM40 on Chromosome 19: From GWAS Catalog, TOMM40 has been
reported as associated with LDL, TG, TC, C-reactive protein [56], Alzheimer’s
disease [57], metabolic syndrome [58].
MAFB on Chromosome 20: From GWAS Catalog, MAFB has been re-
ported as associated with LDL, TC [26], serum total protein level [59], triglycerides
[16].
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